Suzano SA

“Suzano is a structurally superior cost producer with a durable, widening eucalyptus moat and real demand tailwinds in Asian tissue markets, but the Cerrado buildout left the balance sheet at ~5x Net Debt/EBITDA, turning equity into a leveraged bet on BHKP prices over which the company has zero control. At 4.7x trailing P/E and 1.2x book the stock screens cheap, but the EV already prices in the quality while the equity residual carries the full brunt of leverage. Family-control governance and a demonstrated willingness to pile on debt for empire-building acquisitions limit compounding potential for minority shareholders. The right action is to monitor for meaningful deleveraging toward 2.5–3x ND/EBITDA or a price pullback that rebuilds margin of safety — at that point the structural cost moat and secular demand growth make this a compelling long-term entry.”